153 related articles for article (PubMed ID: 31973231)
1. Novel Peptide CM 7 Targeted c-Met with Antitumor Activity.
Xia C; Wang Y; Liu C; Wang L; Gao X; Li D; Qi W; An R; Xu H
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973231
[TBL] [Abstract][Full Text] [Related]
2. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
3. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
[TBL] [Abstract][Full Text] [Related]
4. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of c-Met using a non-standard macrocyclic peptide in gastric carcinoma.
Hwang DW; Bahng N; Ito K; Ha S; Kim MY; Lee E; Suga H; Lee DS
Cancer Lett; 2017 Jan; 385():144-149. PubMed ID: 27810404
[TBL] [Abstract][Full Text] [Related]
6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
7. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.
Kim JS; Kim MY; Hong S
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892160
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
9. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
10. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.
Mady MS; Mohyeldin MM; Ebrahim HY; Elsayed HE; Houssen WE; Haggag EG; Soliman RF; El Sayed KA
Bioorg Med Chem; 2016 Jan; 24(2):113-22. PubMed ID: 26692349
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
[TBL] [Abstract][Full Text] [Related]
15. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
16. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
[TBL] [Abstract][Full Text] [Related]
17. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
18. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
19. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
20. Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures.
Furlan A; Roux B; Lamballe F; Conti F; Issaly N; Daian F; Guillemot JF; Richelme S; Contensin M; Bosch J; Passarella D; Piccolo O; Dono R; Maina F
PLoS One; 2012; 7(10):e46738. PubMed ID: 23071625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]